Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Fibril-associated Collagen01:11

Fibril-associated Collagen

Fibril-associated collagens are a type of collagens present in the extracellular matrix with interrupted triple helices or FACIT (Fibril-associated collagens interrupted triple-helices). FACIT help connect and attach the collagen fibrils with each other as well as with other proteins of the extracellular matrix.
For example, the type II collagen fibrils in cartilage have covalently bound type IX fibril-associated collagens at regular intervals. Other types of fibril-associated collagens are...
Export of Misfolded Proteins out of the ER01:32

Export of Misfolded Proteins out of the ER

After folding, the ER assesses the quality of secretory and membrane proteins. The correctly folded proteins are cleared by the calnexin cycle for transport to their final destination, while misfolded proteins are held back in the ER lumen. The ER chaperones attempt to unfold and refold the misfolded proteins but sometimes fail to achieve the correct native conformation. Such terminally misfolded proteins are then exported to the cytosol by ER-associated degradation or ERAD pathway for...
Protein Translocation Machinery on the ER Membrane01:28

Protein Translocation Machinery on the ER Membrane

The translocon complex situated on the ER membrane is the main gateway for the protein secretory pathway. It facilitates the transport of nascent peptides into the ER lumen and their insertion into the ER membrane.
Sec61 protein conducting channel
In eukaryotes, the translocon complex comprises a core heterotrimeric translocator channel called the Sec61 complex. This channel includes three transmembrane proteins, Sec61α, Sec61β, and Sec61γ, and is the largest subunit of the translocon complex.
Endoplasmic Reticulum01:39

Endoplasmic Reticulum

The Endoplasmic Reticulum (ER) in eukaryotic cells is a substantial network of interconnected membranes with diverse functions, from calcium storage to biomolecule synthesis. A primary component of the endomembrane system, the ER manufactures phospholipids critical for membrane function throughout the cell. Additionally, the two distinct regions of the ER specialize in the manufacture of specific lipids and proteins.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tumor CTR1 Expression and Systemic Copper Dynamics Converge on a Copper Axis in High-Grade Triple-Negative Breast Cancer.

Cancer research communications·2026
Same author

PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor Degraders for Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.

Targeted oncology·2025
Same author

A Cross Attention Approach to Diagnostic Explainability Using Clinical Practice Guidelines for Depression.

IEEE journal of biomedical and health informatics·2024
Same author

Evolving Management of Breast Cancer in the Era of Predictive Biomarkers and Precision Medicine.

Journal of personalized medicine·2024
Same author

Cancer Epidemiology in the Northeastern United States (2013-2017).

Cancer research communications·2023
Same author

Diagnostic Efficacy of LAMP Assay for Human Fungal Pathogens: a Systematic Review and Meta-analysis.

Current fungal infection reports·2023
Same journal

Clinical Validation of a Multiplex Urine Biomarker Assay for Surveillance of Recurrent Bladder Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

Epigenetic Liquid Biopsy Enables Universal Mutation-Agnostic Molecular Surveillance for High-Risk Neuroblastoma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

Claudin 18.2 Targeting: A Pan-Cancer Perspective.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

High-Sensitivity ctDNA Analysis Uncovers Relevant Signals Missed by NGS in Pancreatic Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

Pediatric Brain Tumor Consortium phase 1 study of CD40 agonist sotigalimab in pediatric and young adult patients with recurrent CNS tumors and newly-diagnosed DIPG.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

A randomized phase 2 study of combination atezolizumab and varlilumab (CDX-1127) with or without cobimetinib in previously-treated unresectable biliary tract cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
See all related articles

Related Experiment Video

Updated: May 30, 2026

Non-chromatographic Purification of Recombinant Elastin-like Polypeptides and their Fusions with Peptides and Proteins from Escherichia coli
07:35

Non-chromatographic Purification of Recombinant Elastin-like Polypeptides and their Fusions with Peptides and Proteins from Escherichia coli

Published on: June 9, 2014

Eribulin mesylate.

Sarika Jain1, Linda T Vahdat

  • 1Department of Medicine, Division of Hematology and Oncology, Weill Cornell Medical College, New York, New York 10065, USA.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|August 24, 2011
PubMed
Summary
This summary is machine-generated.

Eribulin mesylate, a novel microtubule inhibitor, offers improved overall survival for patients with metastatic breast cancer. This synthetic drug presents a manageable side-effect profile, including reduced neuropathy risk.

More Related Videos

Production of Elastin-like Protein Hydrogels for Encapsulation and Immunostaining of Cells in 3D
11:46

Production of Elastin-like Protein Hydrogels for Encapsulation and Immunostaining of Cells in 3D

Published on: May 19, 2018

Doxycycline Loaded Collagen-Chitosan Composite Scaffold for the Accelerated Healing of Diabetic Wounds
10:49

Doxycycline Loaded Collagen-Chitosan Composite Scaffold for the Accelerated Healing of Diabetic Wounds

Published on: August 21, 2021

Related Experiment Videos

Last Updated: May 30, 2026

Non-chromatographic Purification of Recombinant Elastin-like Polypeptides and their Fusions with Peptides and Proteins from Escherichia coli
07:35

Non-chromatographic Purification of Recombinant Elastin-like Polypeptides and their Fusions with Peptides and Proteins from Escherichia coli

Published on: June 9, 2014

Production of Elastin-like Protein Hydrogels for Encapsulation and Immunostaining of Cells in 3D
11:46

Production of Elastin-like Protein Hydrogels for Encapsulation and Immunostaining of Cells in 3D

Published on: May 19, 2018

Doxycycline Loaded Collagen-Chitosan Composite Scaffold for the Accelerated Healing of Diabetic Wounds
10:49

Doxycycline Loaded Collagen-Chitosan Composite Scaffold for the Accelerated Healing of Diabetic Wounds

Published on: August 21, 2021

Area of Science:

  • Oncology
  • Pharmacology
  • Cell Biology

Background:

  • Eribulin mesylate is a synthetic analogue of halichondrin B.
  • It functions as a nontaxane microtubule inhibitor with a distinct mechanism of action.
  • Approved for third-line treatment of metastatic breast cancer refractory to anthracyclines and taxanes.

Purpose of the Study:

  • To review the mechanism of action, pharmacokinetics, preclinical antitumor activity, and clinical trials of eribulin.
  • To evaluate eribulin's efficacy and safety in heavily pretreated metastatic breast cancer patients.

Main Methods:

  • Review of preclinical data and clinical trial results for eribulin.
  • Analysis of overall survival (OS) data comparing eribulin to investigator's choice treatment.
  • Assessment of side-effect profiles, including neutropenia, fatigue, and peripheral neuropathy.

Main Results:

  • Eribulin significantly increased overall survival (median OS: 13.1 months vs. 10.6 months).
  • The drug demonstrated a manageable side-effect profile.
  • Notably, eribulin showed a relatively low incidence of peripheral neuropathy compared to other agents.

Conclusions:

  • Eribulin mesylate represents a valuable therapeutic option for patients with heavily pretreated metastatic breast cancer.
  • Its distinct mechanism, improved survival outcomes, and favorable safety profile support its use in this setting.